Office-use compounding in Colorado

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

Silence is not permission in ColoradoHigh confidence

Section 12-280-120(1) sets up a closed system: no drug may be sold, compounded, dispensed, given, received or held in possession unless it is done in accordance with that section. Distribution channels have to be affirmatively authorised, so the absence of an office-use provision is not a gap that permission falls into.

What a pharmacy may sell a practitionerHigh confidence

Section 12-280-120(5)(a)(II) authorises a casual sale of a drug "in the manufacturer’s sealed container" to a practitioner authorised by law to prescribe it. A compounded preparation is by definition not in a manufacturer’s sealed container, so this authorises casual sales of manufactured drugs, not compounded office stock.

The repealed statuteHigh confidence

C.R.S. § 12-280-120(15)(a) now reads, in full, "Repealed." Its source note records: L. 2021, (15)(a) repealed, SB 21-094, ch. 314, p. 1931, § 10, effective September 1. SB 21-094 was the Board of Pharmacy sunset bill, which aligned Colorado pharmacy regulation with the federal Drug Quality and Security Act.

The repealed ruleHigh confidence

Rule 21.00.20 was titled "Casual Sales/Distribution of Compounded Products". Its former text authorised in-state outlets to distribute compounded product to Colorado-licensed practitioners "for the sole purpose of drug administration", with a 10 percent cap, practitioner-verification recordkeeping, labelling requirements and distribution records. All of it was deleted effective November 30, 2021.This is deletion markup in the filed rule, not inference: the Secretary of State’s own redline for the 2021 docket was downloaded and its tracked revisions enumerated. One revision removes the authorising paragraph in its entirety; another removes the cap, the recordkeeping, the labelling and the distribution-records paragraphs; a third strips "distributed to practitioners, other prescription drug outlets, or other outlets allowed by law or" from the labelling rule.

The "10% cap" is repealed lawHigh confidence

The 10 percent figure lived in the deleted subsection and died with the authority it limited. The 10 percent cap that survives in Colorado law is veterinary, and there is also a five-day veterinary dispensing cap in force until January 1, 2027. Do not confuse either with the unrelated 5 percent figure at § 12-280-120(5)(c), which concerns Department of Corrections transfers.

HB 26-1262 does not reopen the pathwayMedium confidence

Four reasons. The entire grant is prefixed by "If the action is undertaken in accordance with applicable federal and state law", so for a pathway federal law does not permit the grant self-cancels. The anti-restrictive-rulemaking protection at (1.5)(b) covers 503B outsourcing facilities only. The legislature did not extend it to pharmacies compounding under section 503A, and that asymmetry is the strongest internal evidence this is an outsourcing-facility protection rather than an office-use bill. Subsection (1.5)(c) expressly disclaims expanding or altering the board’s authority. And the board has not amended Rule 21.00.20.The first three reasons are high confidence and rest on the text. The fourth is a live conflict rather than a settled reading: Rule 21.00.20’s flat prohibition on nonresident distribution is still on the books, and "state law" in the statutory chapeau arguably includes it. Flagged as legal risk, not resolved.

Sterile and non-sterile alikeHigh confidence

No differentiation for office-use purposes. The repealed rule applied to "compounded products" generally, and the 2026 statute covers a sterile or nonsterile environment under one identical condition. There is no carve-out under which sterile injectable preparations may be held as office stock.

Administer-onlyHigh confidence

Historically explicit — "for the sole purpose of drug administration" — and repealed with the rest of the rule on November 30, 2021. There is currently no administer-only limitation for human office use because there is no human office-use authority for it to limit. The 2026 statute does say providers may "obtain, dispense, or administer", but that clause carries the federal-law condition with it.

LabellingHigh confidence

No "For Office Use Only" or "Not for Resale" legend exists anywhere in Colorado law — the word "office" appears zero times in the compounding rules. The practitioner-distribution language was deleted from the labelling rule effective November 30, 2021, leaving only two non-patient-specific label categories: anticipatory compounding for the pharmacy’s own dispensing, and hospital floor stock. There is no practitioner-office-stock label category in Colorado.

Recordkeeping and reportingHigh confidence

Two years (C.R.S. § 12-280-134(1)(a)). The office-use-specific duty to verify each practitioner’s licence and DEA registration was repealed along with the rule. The only affirmative board reporting duty found is theft of controlled substances within 30 days (§ 12-280-134(7)).

The pathway the statute does nameHigh confidence

Section 12-280-133.5(1) requires a nonresident outsourcing facility to register with the board before distributing compounded prescription drugs in the state, on proof of active FDA registration under section 503B, home-state licensure and the most recent FDA inspection report. By contrast the nonresident pharmacy lane at § 12-280-133(2) applies only to an outlet that ships, mails or delivers pursuant to a prescription order — that lane is architected around patient-specific prescriptions.

Corrections to commonly cited Colorado factsHigh confidence

The compounding rules are the Rule 21.00.00 series, not the 13.00 or 15.00 series — Rule 15.00.00 is Wholesalers. And "Colorado has statutory office-use language" is true only for veterinary medicine, at § 12-280-121. The human provision was § 12-280-120(15)(a) and it is repealed.

Last changeHigh confidence

HB 26-1262 effective June 2, 2026, quoted above. HB 26-1220 effective August 12, 2026, covering behavioural-health emergency kits. HB 26-1198 repeals § 12-280-121(2) and (3) effective January 1, 2027 and relocates them into the Veterinary Practice Act. No Colorado rulemaking has touched the compounding office-use rule since November 30, 2024, and none since HB 26-1262 — so Rule 21.00.20’s prohibitions remain unamended and in tension with the new statute.

Colorado at a glance

Receiving 503B office stock in Colorado

Colorado is structurally the cleanest state reviewed here for the 503B route: HB 26-1262, effective 2 June 2026, expressly authorises a provider to obtain a compounded drug supplied by an outsourcing facility. It is also the state where no board has interpreted any of it.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Colorado asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inHigh confidence

A nonresident 503B outsourcing facility registration with the Board of Pharmacy. C.R.S. § 12-280-133.5(1): such a facility "shall not conduct the business of distributing compounded prescription drugs in this state without first registering with the board as a nonresident 503B outsourcing facility." The application requires proof of active FDA registration, active home-state licensure, and a copy of the most recent FDA inspection report.The Board’s own Licensing Guide misstates this as registration with, and inspection by, the DEA. The statute and the rule both say FDA, and the statute controls. Fees and the renewal cycle sit behind the online application and are not established here.

Does your practice need a permit?High confidence

None — and a private practice could not obtain one if it wanted to. "Other outlet" at § 12-280-103(32) is a closed list of institutional types: hospitals without a pharmacy, federally qualified health centres, ambulatory surgical centres, hospices, jails, schools and the like. A physician practice, med spa or independent clinic is not on it, and §§ 12-280-120(2)(e) and (3)(a)(V) let suppliers sell to "any practitioner authorized by law to prescribe" with no outlet registration on the receiving side.

Administer vs dispenseMedium confidence

An unresolved statutory conflict, and it matters. § 12-280-120(1.5)(a)(III), effective 2 June 2026, says a provider "may obtain, dispense, or administer a compounded drug or device supplied by" a resident or nonresident 503B outsourcing facility, while § 12-280-120(4) provides that "only" a registered prescription drug outlet or other registered outlet may dispense a prescription. Both are in force. In-office administration is the supported case.No Board guidance exists on any of this. The 70-page Board policy manual and the January, March and May 2026 minutes contain zero references to 503B, outsourcing facilities or human office use. Colorado’s position rests on statutory construction, and Rule 21 is inside an open rulemaking.

Scheduled (controlled) stockNot verified

Not researched for Colorado in this review — Article 280 was read and the Medical Practice Act was not. Confirm before holding scheduled stock.

How to check a facility’s credential before you order is set out in how to place an office-use order.

What this page does not establish

• The state regulator’s own site returned an access error on every request, so we reviewed no Board of Pharmacy policy statements, guidance, newsletters or meeting minutes. If the Board has published guidance since HB 26-1262 took effect, it is not reflected here. This is the largest single gap on this page and the first thing to close before relying on it.
• There is no consolidated authenticated copy of 3 CCR 719-1 in circulation. The rule text here is reconstructed from the Secretary of State’s own filed adopted-rules and redline documents plus the official version history — reliable, but not a single authenticated consolidated text.
• The rules were renumbered before a July 2026 correction docket, and whether that changed Rule 21’s numbers is unconfirmed. Cite Colorado rule numbers with caution and check them against the current filing.
• The current text of Rule 21.00.10, the full veterinary sub-conditions at Rule 21.00.20(c)-(d), and the sterile labelling rule were not recovered, so this page does not establish them.
• The former text of the repealed § 12-280-120(15)(a) was never recovered. The repeal itself is confirmed from the official code; what the subsection used to say is inferred rather than read.
• HB 26-1262’s legislative declaration is unread — the signed act PDF carries no text layer — so this page’s reading of that bill is textual only.
• Beyond the primary sources cited here, we have not surveyed board newsletters, declaratory statements, enforcement actions, disciplinary orders or coverage of pending bills. Read nothing into that silence — it means we have not looked, not that nothing is there.